NASDAQ · LKFT

Lakefront Biotherapeutics American

$27.84 -$0.28 (-1.00%) 1D Market open
Charting by TradingView

Key Metrics

$1.84B
Market cap
—
P/E · TTM
—
Revenue · TTM
—
Net income
EPS · TTM —
Dividend yield —
Free cash flow —
Beta · 1Y —
EBITDA · TTM —
Gross margin —

Snapshot

Market cap$1.84B
Enterprise value—
Shares outstanding65.5M
52-wk range$26.42 – $30.91
Avg volume · 20D172.9K
Net cash —
Book value / share—
ExchangeNASDAQ
About Lakefront Biotherapeutics American
IPO dateDec 18, 2008
Employees452

Lakefront Biotherapeutics NV a biopharmaceutical company committed to improving the lives of people with severe diseases. It focuses on delivering medicines with transformational impact for patients by accelerating life-changing science and innovation in areas of high unmet need.

Wolf Grade COMING SOON

—

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E—
P/S—
P/FCF—
EV/EBITDA—
EV/Sales—
Graham №—

Profitability

Gross —
Operating —
Net —
FCF —
ROE / ROIC — · —

Financial Health

Current ratio—
Quick ratio—
Debt / equity—
Debt / EBITDA —
Net cash —
Working capital—

Cash Flow · TTM

Operating CF —
Capex —
Free cash flow —
Buybacks —
Dividends paid —
Shareholder yield —

Piotroski F-Score

0 / 9
Weak fundamentals · 0 of 9 signals passing

Altman Z-Score

—
Insufficient balance-sheet inputs

Graham Number vs Price

—
Requires positive earnings and book value
Fundamentals through 2025-12-31 · computed by TickerWolf from SEC filings